drugset / Trial / NCT00276042

A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media

NCT00276042 ↗

Phase 2 Completed 328 enrolled Replidyne
RandomizedParallel-groupDouble-blindTreatment

Summary

The study will be conducted in infants and children with acute otitis media, 6 months to less than 7 years old, in Costa Rica and Israel. The primary objective of this trial will be to describe bacteriologic efficacy in those with initial culture positive specimens with different dosages of faropenem

Timeline

Start
2006-01
Primary completion
2007-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Faropenem Medoxomil Small molecule — —

Indications